Retatrutide TRIUMPH-1 (2023) and TRIUMPH-2 (2024) TRIUMPH-1 (Jastreboff et al., NEJM 2023): 338 non-diabetic adults with obesity, 48 weeks at escalating doses: 12 mg dose: 24.2% weight loss 8 mg dose: 22.8% 4 mg dose: 17.5% Placebo: 2.1% TRIUMPH-2 (Rosenstock et al., Lancet 2024) confirmed effects in T2D patients with concurrent NAFLD improvement (hepatic fat reduction 54% at 24 weeks, 12 mg dose)
References: [1] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH
Fahrenholtz, C
Efectos sobre la prdida de peso, composicin corporal y prevencin de diabetes El programa SURMOUNT muestra que TZP reduce el peso de forma dosis-dependiente, alcanzando un 22,5% de reduccin ponderal con la dosis mxima semanal de 15mg40 (tabla 1)
Anti-Aging and Longevity: By increasing growth hormone, it supports cell regeneration, reducing visible signs of aging like wrinkles and loose skin, and enhancing overall skin health